Please assess the completion status of the following clinical trial:

Trial Title: Effect of the Inhibitors of the Way JAK-STAT on Regulatory B Cells

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* General criteria~* Patient, of 18 and more years old~* Subject affiliated to a social security system~* Subject not being in period of exclusion with regard to another protocol~* Absence of pregnancy in the inclusion (date of the last period, use of a contraceptive method, ß -HCG impulsive person in case of doubt)~* Informed consent~* Criteria of inclusion of the group rheumatoid arthritis (in vitro studies):~* Rheumatoid arthritis, corresponding to the the classification ACR / EULAR 2010 criteria~* Criteria of inclusion of the group arthritis (in vitro studies):~* Spinal degenerative osteoarthritis or degenerative osteoarthritis of the members, according to the clinical and radiological elements.~* Criteria of inclusion of the group rheumatoid arthritis, longitudinal study at the patients treated by JAK / STAT inhibitors :~* Rheumatoid Polyarthritis, corresponding to the classification ACR / EULAR 2010 criteria~* Patient to whom a treatment by inhibitor of the way JAK / STAT was proposed in current care of rheumatoid arthritis.~Exclusion criteria:~* General criteria~* Corticosteroid therapy superior to 10 mg / j~* Drip of corticoids in the previous month~* Pregnant or breast-feeding Patients~* Patient under protection(saving) of justice~* Under guardianship Patient or guardianship~* Current Infection~* Criteria of non-inclusion of the group rheumatoid polyarthritis ( in vitro studies):~* Treatment by immunomodulateur or biotherapics (anti-TNF alpha, tocilizumab, abatacept or rituximab) in the previous year~* Criteria of non-inclusion of the group arthritis ( in vitro studies):~* History of autoimmune disease or néoplasie~* Treatment by immunomodulateur or biotherapics (anti-TNF alpha, tocilizumab, abatacept or rituximab)~* Criteria of non-inclusion of the group rheumatoid arthritis, longitudinal study at the patients treated by JAK / STAT inhibitors :~Treatment by rituximab in the previous year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Rheumatoid arthritis (Type: OTHER): Patients responding to ACR/EULAR 2010 criteria and Blood sample analysis of patients treated as standard care
- Osteoarthritis (Type: OTHER): Control patients and Blood sample analysis of patients treated as standard care
- Rheumatoid arthritis with JAK/STAT inhibitors (Type: OTHER): Standard use of JAK/STAT inhibitors and Blood sample analysis of patients treated as standard care

Based on this trial design, predict the completion outcome and termination type (if applicable).